IDEXX Laboratories, Inc. (IDXX) Stock Analysis 2026

HealthcareDiagnostics & Research
$575.98
as of 2026-10-29
-21.6% (52-week)50D MA $558.99  |  200D MA $610.27

BriMind AI Score

Proprietary
52
Neutral
Price CAGR
18.2%
1Y Return
-12.6%
Analyst Upside
+24.7%
Rev Growth
9.7%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

IDXX Revenue & Profitability Breakdown

This chart shows how IDXX's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$4.55B
Cost of Revenue
-$1.71B
Gross Profit
$2.84B62.4% margin
Operating Expenses
-$1.25B
Operating Income
$1.59B35.0% margin
Tax & Other
-$453.0M
Net Income
$1.14B25.0% margin
Gross Margin
62.4%
Operating Margin
35.0%
Net Margin
25.0%
EBITDA Margin
34.1%

Key Financial Metrics

IDEXX Laboratories, Inc. trades at a trailing P/E of 39.06x, generates $909.4M in free cash flow, runs a debt/equity ratio of 67.97, and converts shareholder equity into profit at a 74.2% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$43.72B
Enterprise Value
$43.11B
P/E (Trailing)
39.06
P/E (Forward)
33.15
PEG Ratio
3.40
EV / EBITDA
32.13
Price / Sales
10.74
Price / Book
29.27
Revenue
$4.55B
Revenue Growth
9.7%
Earnings Growth
17.6%
EBITDA
$1.34B
Gross Margin
62.4%
Operating Margin
35.0%
Net Margin
25.0%
Return on Equity
74.2%
Return on Assets
27.1%
Free Cash Flow
$909.4M
Total Cash
$164.0M
Total Debt
$1.06B
Debt / Equity
67.97
Current Ratio
1.17
Quick Ratio
0.73
Beta
1.54
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.2%
Inst. Ownership
96.8%
Short % Float
2.8%
Book Value / Share
$20.45

Wall Street Analyst Consensus

12 analysts covering IDEXX Laboratories, Inc. currently lean toward a Hold rating, with a mean 12-month price target of $698.92 (+21.3% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingHold(12 analysts)
SellStrong Buy
Low Target$385.00-33.2%
Mean Target$698.92+21.3% upside
High Target$577.00+0.2%

Intrinsic Value Estimates for IDXX

We use 1 valuation model to estimate IDXX's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

IDXX is currently in a short-term uptrend, trading above its 50-day average of $558.99 and below its 200-day average of $610.27. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$575.98
50-Day MA
$558.99
▲ Price above
200-Day MA
$610.27
▼ Price below
Short-term Uptrend
Above 50-day MA but mixed longer-term
Read the full IDXX in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for IDXX.

Compare IDXX with Peers

ZTS vs IDXXZoetis vs IDEXX Laboratories — Animal Health Pharma vs
IDXX vs DXCMIDEXX Laboratories vs DexCom — Veterinary Diagnostics L
IDXX vs EWIDEXX Laboratories vs Edwards Lifesciences — Veterinary
MOH vs IDXXMolina Healthcare vs IDEXX Laboratories — Medicaid Mana
SPG vs IDXXSimon Property Group vs IDEXX Laboratories — Mall REIT
CHWY vs IDXXChewy vs IDEXX Laboratories — Pet E-Commerce Retailer v

Further Reading

Research and guides that put IDXX’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Market Theory10-Year Treasury Yield Hits 19-Year High: What 5.2% Means for StocksRisk ManagementBest ETFs for a Recession-Proof Portfolio in 2026FundamentalsHow to Read a 10-K Annual Report: Complete Investor GuideFundamentals10 Stock Analysis Tools Every Investor Should Know About

More Healthcare Stock Analysis

In-depth reports on companies operating alongside IDXX — business models, bull and bear cases, and the metrics that matter.

TMOThermo Fisher Scientific Inc.Diagnostics & ResearchNTRANatera, Inc.Diagnostics & ResearchDHRDanaher CorporationDiagnostics & ResearchPRMEPrime Medicine, Inc.BiotechnologyHCAHCA Healthcare, Inc.Medical Care FacilitiesHUMHumana Inc.Healthcare PlansVEEVVeeva Systems Inc.Health Information ServicesALNYAlnylam Pharmaceuticals, Inc.Biotechnology

Unlock the Full IDXX Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis